Page last updated: 2024-11-05

aminopentamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

aminopentamide: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID176163
CHEMBL ID3561133
SCHEMBL ID203612
MeSH IDM0059974
PubMed CID22565
CHEMBL ID92915
CHEBI ID91829
SCHEMBL ID251458
MeSH IDM0059974

Synonyms (129)

Synonym
dimevamide sulfate
aminopentamide acid sulfate, dl-
centrine
aminopentamide sulphate
aminopentamide hydrogen sulfate
HMS2093B10
bl 139 sulfate
aminopentamide sulfate
niosh/yv4430000
YV44300000
4-(dimethylamino)-2,2-diphenylvaleramide sulfate
aminopentamide sulfate (usp)
D09703
valeramide, 4-(dimethylamino)-2,2-diphenyl-, sulfate (1:1)
(2-(2-(dimethylammonio)propyl)-1-oxo-2,2-diphenylethyl)ammonium sulphate
20p9ni883o ,
unii-20p9ni883o
unii-3qf2626u6o
35144-63-9
aminopentamide sulfate [usp]
20701-77-3
aminopentamide sulfate [usan]
benzeneacetamide, alpha-(2-(dimethylamino)propyl)-alpha-phenyl-, sulfate
gamma-dimethylamino-alpha,alpha-diphenylvaleramide sulfate
einecs 252-394-0
pharmakon1600-01505650
nsc759162
alpha-(2-(dimethylamino)propyl)-alpha-phenylbenzeneacetamide sulfate
dimevamide sulfate [mart.]
aminopentamide hydrogen sulfate [green book]
.alpha.-(2-(dimethylamino)propyl)-.alpha.-phenylbenzeneacetamide sulfate
aminopentamide sulfate [usp monograph]
valeramide, 4-(dimethylamino)-2,2-diphenyl-, sulphate (1:1)
.alpha.-(2-(dimethylamino)propyl)-.alpha.-phenylbenzeneacetamide sulphate
aminopentamide sulfate [usp-rs]
4-(dimethylamino)-2,2-diphenylvaleramide hydrogen sulfate
CCG-213500
SCHEMBL203612
dtxcid5031393
NCGC00263910-02
tox21_113961
cas-20701-77-3
dtxsid7057604 ,
CHEMBL3561133
5897-62-1
SR-05000001938-1
sr-05000001938
4-(dimethylamino)-2,2-diphenylpentanamide sulfate
4-(dimethylamino)-2,2-diphenylpentanamide;sulfuric acid
Q27253478
4-(dimethylamino)-2,2-diphenylpentanamide xsulfate
CS-0013320
aminopentamide (monosulfate)
dimevamide sulfate (mart.)
aminopentamide sulfate (usp-rs)
aminopentamide sulfate (usp monograph)
alpha-(2-(dimethylamino)propyl)-alpha-phenylbenzeneacetamide sulphate
dimevamide
nsc-759162
aminopentamide
CHEMBL92915
bl-139
4-(dimethylamino)-2,2-diphenylpentanamide
dimevamidum [inn-latin]
benzeneacetamide, alpha-(2-(dimethylamino)propyl)-alpha-phenyl-
60-46-8
valeramide-om
4-dimethylamino-2,2-diphenylvaleramide
ip1b47l61m ,
dimevamidum
nsc 759162
dimevamida [inn-spanish]
dimevamida
valeramide, 4-(dimethylamino)-2,2-diphenyl-
alpha,alpha-diphenyl-gamma-dimethylaminovaleramide
dl-aminopentamide
einecs 200-479-8
dimevamide [inn]
unii-ip1b47l61m
alpha-(2-(dimethylamino)propyl)-alpha-phenylbenzeneacetamide
bl 139
BRD-A69917777-065-01-4
SCHEMBL251458
dimevamide [mart.]
5985-87-5
aminopentamide [mi]
benzeneacetamide, .alpha.-(2-(dimethylamino)propyl)-.alpha.-phenyl-
.alpha.-(2-(dimethylamino)propyl)-.alpha.-phenylbenzeneacetamide
dimevamide [who-dd]
DTXSID2057605 ,
dimevamid
AB01563100_01
CHEBI:91829
F20770
SBI-0206820.P001
aminopentamide sulfate (200 mg)
aminopentamide sulfate(200 mg)
Q27163625
mfcd00865194
DB15597
centrine, (-)-
5985-88-6
bl-139, (+)-
valeramide-om, (+)-
unii-hi3dvh9wmi
valeramide, 4-(dimethylamino)-2,2-diphenyl-, (+)-
dimevamide, (+)-
dimevamide, (-)-
alpha,alpha-diphenyl-gamma-dimethylaminovaleramide, (-)-
aminopentamide, (+)-
6078-64-4
valeramide, 4-(dimethylamino)-2,2-diphenyl-, (-)-
unii-661tmo8um4
aminopentamide, (-)-
benzeneacetamide, alpha-(2-(dimethylamino)propyl)-alpha-phenyl-, (+)-
bl-139, (-)-
hi3dvh9wmi ,
centrine, (+)-
661tmo8um4 ,
valeramide-om, (-)-
BCP32413
dimevamida;4-dimethylamino-2,2-diphenylva-leramide;bl-139
bl 139; centrine; dimevamide; valeramide-om; dl-aminopentamide
.alpha.,.alpha.-diphenyl-.gamma.-dimethylaminovaleramide, (-)-
benzeneacetamide, .alpha.-(2-(dimethylamino)propyl)-.alpha.-phenyl-, (+)-
dimevamide (mart.)
dtxcid0031394
dimevamida (inn-spanish)
dimevamidum (inn-latin)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency8.25430.000714.592883.7951AID1259369; AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.04740.003041.611522,387.1992AID1159552; AID1159553
cytochrome P450 2D6Homo sapiens (human)Potency7.76190.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (28.57)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's3 (21.43)24.3611
2020's6 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]